Local Injections in Polymyalgia Rheumatica

To the Editor:

We read with interest the article by Salvarani and colleagues. The authors postulate that shoulder corticosteroid injections seem to be an effective and safe therapy for polymyalgia rheumatica (PMR). They expound that the shoulder bursitis, joint synovitis, and tenosynovitis seen in PMR respond very well to corticosteroid therapy. They also claim that the bicipital tendon, subacromial and subdeltoid bursae, and glenohumeral joint, which are especially affected by the inflammatory process, are communicating synovial structures, so that just a single injection could completely alleviate joint pain. Moreover, at the very end of the article, it is stated that the articular and extracapsular synovial structures of the hip are not in communication, in contradistinction to the shoulder, and thus multiple site injections could be required for hip infiltration corticosteroid therapy. However, it has already been established that the bursae lie between the rotor cuff (mainly supraspinatus muscle) and the overlying acromion; they do not communicate with the joint. If there is a communication, it implies a complete rupture of the rotor cuff (mainly supraspinatus). Full thickness tears of supraspinatus tendon are found in 7-27% of patients at autopsy. The number of these tears increases with age and PMR can be considered as a disease of the elderly. The incidence of full thickness tears is about 20-30%. Magnetic resonance imaging evaluation of older asymptomatic patients (60 years of age and above) showed an incidence of 28% full thickness tears. Consequently, the probability of an injection into the joint reaching the subacromial bursa is only one in three patients. Furthermore, in the study by Salvarani, et al. the patients with MRI reported did not show any full thickness tears; however, the injection into the joint still led to the correction of the subacromial bursitis. This brings up the question whether the response is due to the systemic effects of the corticosteroid injection or not. We think that the answer to this question lies in a study that compares the effects of systemic corticosteroid administration, local corticosteroid injection, and multiple site injection, including the subacromial space.

KENAN AKGUN, MD, Department of Physical Medicine and Rehabilitation; ONDER AYDINGOZ, MD, Department of Orthopaedics and Traumatology, Cerrahpasa Medical Faculty, Istanbul, Turkey.

REFERENCES

Dr. Salvarani, et al reply

To the Editor:

We are grateful to Akgun and Aydingoz for their interesting comment on our paper. As they underline, there is an increased incidence in polymyalgia rheumatica (PMR) of rotator cuff tears with aging. In autopsy series rotator cuff defects were observed in 30% of subjects who were in their 50s and 60s, and in 90% to 100% of those who were over the age of 70. As most of our patients with PMR were in their 70s, a communication between glenohumeral joint cavity and subacromial and subdeltoid bursae was probable. However, as mentioned in our report, we cannot exclude that part of the efficacy of the therapy could be related to the systemic absorption of corticosteroids.

CARLO SALVARANI, MD, Divisione di Reumatologia, Arcispedale S. Maria Nuova, Reggio Emilia; PABRIZIO CANTINI, MD, Unità di Reumatologia, Medicina 2, Ospedale Civile, Prato; IGNAZIO OLIVIERI, MD, Dipartimento di Reumatologia, Ospedale San Carlo, Potenza, Italy.

REFERENCES


To the Editor:

In a recent issue of The Journal, Neher, et al1 stressed the value of visual hallucinations (VH) as a harbinger of permanent visual loss (PVL) in patients with giant cell arteritis (GCA). These authors found that intermittent VH preceded PVL in 4 of 5 patients with that severe manifestation. If their finding is confirmed, the report of VH by a patient with suspected GCA will have important implications for ophthalmologic investigation and treatment urgency. We describe our experience based on a large series of patients with GCA, which might clarify the relationship between VH and PVL.

Between 1977 and 2001, we diagnosed 203 patients as having temporal arteritis, including 165 biopsy proven cases. Specifically, patients were asked if they had noticed transient eye manifestations such as pain, visual loss, blurred vision, diplopia, and VH, including dazzling flash, glittering, colored pastille illusions or more complex hallucinations. Date of onset and
duration and recurrence of eye symptoms were also prospectively recorded, using a comprehensive questionnaire. Visual events occurred in 54 patients (27% of cases), including transient symptoms in 39 and PVL in 26 (anterior ischemic optic neuropathy in 23, central retinal artery occlusion in one, and retrobulbar ischemic optic neuropathy in 2). Only 4 patients improved their vision upon starting glucocorticoid treatment, while 4 developed definitively and bilaterally blind. Most of these cases have been published⁴ The figures show the relative frequency of VH and other transient visual symptoms, according to whether the patients developed PVL or not. The most frequently reported type of transient visual symptom was amaurosis fugax (19 cases), followed by VH (14 cases). Transient visual symptoms heralded PVL in 11 patients (42% of cases). The delay to PVL from the first episode of visual symptom ranged from less than one day to 18 days (average 6 days). All 3 patients with VH preceding PVL also recalled at the same time concurrent amaurosis fugax or diplopia. As shown in Table 1 the risk of PVL was significantly associated with a history of transient visual symptoms, amaurosis fugax, more than one type of symptom in the same patient, and symptom recurrence, but not with blurred vision, diplopia, or VH (p = 0.39).

Our results confirm the relatively high frequency of VH in patients with GCA, but do not support the value of VH alone as a harbinger of impending PVL. We showed recently, using logistic regression analysis, that the only risk factor for the development of PVL was an elevated blood platelet count, although a history of transient visual ischemic symptoms had marginal significance⁵ However, a stronger association might have been overshadowed. For example, nonrelapsing, fleeting, or bizarre symptoms may have been underreported or underrecognized by patients, especially those with already impaired vision or memory problems. Moreover, the risk of developing PVL after VH may be underestimated in our series, since many such patients recalled additional amaurosis fugax, blurred vision, or transient diplopia and therefore received prophylactic pulse glucocorticoids. Nevertheless, before the relationship between VH and PVL in patients with GCA is fully elucidated, a thorough ophthalmologic anamnesis, including

<table>
<thead>
<tr>
<th>Table 1. Value of transient visual ischemic symptoms in predicting permanent loss in 203 patients with temporal arthritis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Permanent Visual Loss, n = 26</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Transient visual ischemic symptoms</td>
</tr>
<tr>
<td>Amaurosis fugax</td>
</tr>
<tr>
<td>Blurred vision</td>
</tr>
<tr>
<td>Diplopia</td>
</tr>
<tr>
<td>Visual hallucinations</td>
</tr>
<tr>
<td>Eye pain</td>
</tr>
<tr>
<td>More than one type of symptom</td>
</tr>
<tr>
<td>Recurrence of symptoms</td>
</tr>
</tbody>
</table>

* Identical or new symptom. † Data were missing for 1 patient with PVL and 3 patients with transient visual symptoms alone. # Fisher's exact test. NS not significant (p > 0.1).

VH, should be part of the clinical assessment of patients with suspected GCA.

ERIC LIOZON, MD; KIM LY, MD; VÉRONIQUE LOUSTAUD, MD; ELISABETH VIDAL, MD; Professor and Head, Service de Médecine Interne A, Hôpital Universitaire Dupuytren, 87042 Limoges, France. E-mail: eric.liozon@unilim.fr

REFERENCES
2. Liozon E, Herrmann FR, Jauberteau MO, et al. Facteurs prédictifs de complications céphaliques ischémiques irréversibles au cours de

![Figure 1. Relative frequency of various transient visual manifestations in 28 patients who did not develop permanent visual loss.](image1)

![Figure 2. Relative frequency of various transient visual manifestations in 11 patients who developed permanent visual loss.](image2)
Dr. Nesher, et al reply

To the Editor:

We thank Dr. Liozon and colleagues for their comments and additional data. The main purpose of our report was to draw attention to visual hallucinations being part of the ophthalmologic symptoms associated with giant cell arteritis (GCA), and their letter contributes to this purpose.

In our report, visual hallucinations were common among GCA patients with ophthalmologic manifestation, and preceded visual loss in 4 of them. The data reported by Liozon, et al are not in contradiction with our data. They also showed that visual hallucinations occur quite frequently, in 14 of 54 GCA patients with eye symptoms. This figure supports our impression that this phenomenon is much more common than previously estimated. In our experience patients are initially quite reluctant to disclose such information, fearing they would be labeled as “insane,” and describe their experience only after establishing good rapport with the physician and being reassured that those visions can be part of their vasculitis.

In Liozon’s study visual loss developed in only 3 of the 14 cases that experienced hallucinations, while in our report all 4 patients developed permanent visual loss. This difference is likely to be the result of the therapeutic intervention with steroids: no patient reported by us received steroid treatment prior to the visual loss, while many of the patients reported here received prophylactic pulse glucocorticoids after the initial visual symptom. This explanation is supported by our recent observation of 2 patients presenting with new onset headaches, slight blurring of vision, and visual hallucinations. Prompt treatment with 60 mg/day prednisone resulted in rapid improvement of symptoms and cessation of the hallucinations. No patient developed further visual impairment. Temporal artery biopsies subsequently showed arteritis in both cases.

Both reports suggest that visual hallucinations are not rare in GCA, and along with amaurosis fugax, blurred vision, and diplopia, should be regarded as symptoms necessitating prompt treatment with steroids to prevent irreversible visual loss.

GIDEON NESHER, MD, RONIT NESHER, MD, YAACOV ROZENMAN, MD, MOSHE SONNENBLICK, MD, Shaare-Zedek Medical Center, Jerusalem 91031, and Sapir Medical Center, Kfar-Saba 44281, Israel.

Isolated Tuberculosis Monoarthritis Mimicking Juvenile Rheumatoid Arthritis

To the Editor:

We read with interest the cases of childhood onset tuberculous arthritis presented by Al-Matar, et al, and would like to report another case that highlights the resurgence of this disease, not only in North America but also in the United Kingdom, Europe, and other areas. This case highlights the potential for mimicry of more than one type of juvenile idiopathic arthritis (JIA) (formerly juvenile rheumatoid arthritis).

Case history. A 13-year-old UK born Asian girl was referred to our tertiary level pediatric rheumatology unit in July 1998 with a provisional diagnosis from the referring unit of probable JIA, unresponsive to treatment. The relevant history started 6 months previously in January 1998, when she developed persistent pain, swelling, and a decreased range of motion (ROM) of her right elbow joint. Shortly thereafter she developed an abscess in the right buttock that required surgical drainage and she was treated with flucloxacillin at the referring hospital. Over the following 3 months she also progressed to develop pain and swelling of the right shoulder (anterior glenohumeral and acromioclavicular region), discomfort in both knees, and increasing deformity of the right elbow. She was treated with nonsteroidal antiinflammatory drugs with little improvement. In addition to this she developed further series of deep seated abscesses in the left buttock, left thigh, left breast, and a 5 x 5 cm abscess on the scalp. Although she was treated with broad spectrum antibiotics and surgical drainage, healing was slow.

During the 6 months prior to her referral she had a low grade pyrexia and occasional mouth ulcers. Initial investigations at her local pediatric unit showed hemoglobin 9.1 g/dl, white blood cells (WBC) 8.2 x 10^9/L, and erythrocyte sedimentation rate (ESR) 131 mm/h. The previous medical history was unremarkable; there was no history of contact with tuberculosis on admission to our hospital (although language difficulties made ascertainment difficult), and she had received Bacillus Calmette-Guerin (BCG) at birth.

On general examination at our unit, she was found to have low grade pyrexia with maximum temperature of 38.5°C, but no lymphadenopathy, rash, oral ulcers, or alopecia. Skin examination revealed a 2 x 2 cm ulcerated area on the right buttock, with healing scars on the thigh, breast, and scalp at the site of previous abscesses. She also had a 3 x 3 cm subcutaneous swelling over the posterolateral aspect of the right thorax (Figure 1). General examination was otherwise unremarkable. On musculoskeletal review she had a markedly swollen and warm right elbow with ROM of only 80°-100° of flexion, indicating a marked fixed flexion deformity. The right acromioclavicular joint was warm and swollen, with painful but full movement of the adjacent glenohumeral joint. The right wrist joint was swollen, with reduced extension, and both knees had small effusions. All other joints including the spine were normal on initial examination.

Figure 1. Posterior view of the trunk one week after presentation showing a soft tissue swelling over the posterolateral ribs on the right and a mid-thoracic swelling as well, representing 2 cold abscesses.

Correspondence
The initial working diagnosis in our unit was "partially treated" infectious (septic) arthritis, with multiple associated abscesses. In view of the unusual nature of presentation, other underlying diagnoses were considered, including a primary immune deficiency presenting at an older age, or an evolving autoimmune disease with or without coexistent chronic inflammatory joint disease.

Investigations revealed normocytic normochromic anemia with a hemoglobin of 9.6 g/dl, WBC 8.0 x 10^9/l, platelets 211 x 10^9/l, elevated acute phase response with both ESR and C-reactive protein significantly elevated to 100 mm/h and 100 μ/l, respectively. Radiographs of the involved joints showed periarticular osteoporosis, reduced joint space, and deformity of subchondral bone (Figure 2). Electrolytes, blood sugar, and renal function were normal and blood cultures were negative. She was negative for rheumatoid factor, antinuclear antibody, extractable nuclear antigen, and dsDNA. Complement levels were normal, as were a lymphocyte subset panel, nitroblue tetrazolium test, and neutrophil adhesion test.

Arthrocentesis revealed frank pus from the right elbow and the right acromioclavicular joint. She thus underwent formal arthroscopy, synovial biopsy, and washout of the 2 involved joints.

A Mantoux test with 1:1000 PPD (purified protein derivative) on day 2 was, however, strongly positive at 23 mm, and antituberculosis treatment was started the following day. A chest radiograph was normal. The synovial biopsy revealed multiple tubercular granulomas (Figure 3) and a punch biopsy from the ulcer on the right buttock showed multiple giant cells with epithelioid granuloma. Polymerase chain reaction (PCR) from the pus aspirated from right elbow was positive for *Mycobacterium tuberculosis*, and culture from the elbow and the shoulder was subsequently positive.

The final diagnosis was thus multifocal osteoarticular tuberculosis. It was at this stage the family revealed that the maternal grandmother had had pulmonary tuberculosis in the last year, and indeed that she had been in close contact with our patient! As she had previously received BCG vacci-

![Figure 2. Plain radiograph of the right elbow joint revealing marked abnormalities of the bony contours and density. There is significant soft tissue swelling overlying and enlargement of all bony components of the elbow with some periosteal reaction.](image)

![Figure 3. Photomicrograph of synovial tissue from the right acromioclavicular joint at presentation. The histology reveals a typical tubercular granuloma.](image)
An elevated ESR, unusual patterns of joint involvement in childhood arthritides, or resistance to initial therapy should prompt the attending physician to consider a Mantoux test to help exclude TB. The test was positive in our patient, as has been previously reported in the majority of children and adults with osteoarticular TB. An elevated ESR and positive Mantoux, while helpful, are neither specific nor completely reliable. The definitive diagnosis of osteoarticular TB requires the identification of M. tuberculosis from the site. Optimally the patient should have a synovial biopsy, as histological examination reveals granuloma in 88% of cases, and the culture from tissue is positive in over 90%. Our patient had a positive biopsy and culture and was also smear positive, which has been noted in 25 to 33% of specimens. PCR techniques are being used increasingly for diagnosis of a number of different conditions that previously relied on laborious culture methods, and in this case provided rapid confirmation of strongly suggestive pathology. As the incidence of multi-drug resistant TB increases, recovery of the specific organism is important, especially if the index case is not identified. Most patients respond well to drug therapy, and surgery is rarely required.

In conclusion, although this case differs from that of Al-Matar, et al in several respects, it highlights the increasing diagnostic challenge facing physicians dealing with joint problems in childhood; moreover, in our patient, a rare mimic of JIA, vigilance and careful history taking and clinical examination should prompt early recognition, treatment, and an optimal outcome.

SUKIATA SAWHNEY, MBBS, MRCP, KEVIN J. MURRAY, MBBS, FRACP, Pediatric Rheumatology Unit, Great Ormond Street Hospital, London, UK.

REFERENCES

Drs. Al-Matar, et al reply

To the Editor:

We read with interest the letter by Sawhney and Murray describing a child with severe tuberculous arthritis. This diagnosis, recently considered to be a rare event in the developed world, is emerging as a disease to seriously consider in the differential diagnosis of chronic arthritis of childhood.

The patients we reported were very different from the patient described by Sawhney and Murray in that they had monoarthritis and no extraarticular disease. The patient they described had monoarthritis of the elbow quickly followed by multiple soft tissue abscesses. In hindsight a diagnosis of tuberculous arthritis was likely. (Wouldn’t we all like to exchange hindsight for foresight?) The systemic nature of this patient’s illness — fever, multiple abscesses, very high erythrocyte sedimentation rate and C-reactive protein — all pointed to an infectious or malignant disease. Our patients were systematically entirely well and looked like oligoarticular juvenile idiopathic arthritis. The indicator that this was not the case was their nonresponsiveness to intraarticular corticosteroids. The difficulty in obtaining a history of exposure to tuberculosis was our experience as well.

It could be argued that the application of a Mantoux test should be a standard practice in dealing with any child with monoarthritis if it is in any way atypical, or in children with atypical polyarthritis, even if there is a history of bacillus Calmette-Guérin immunization and denial of exposure to active tuberculosis. We must routinely consider the possibility of tuberculous arthritis in this patient population.

MOHAMMED AL-MATAR, MBBS, MAPP, DAVID A. CABRAL, MBBS, FRCP; ROSS E. PETTY, MD, PhD, Department of Pediatrics, University of British Columbia, Vancouver BC, Canada.

REFERENCES


Termination of Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis

To the Editor:

The experience reported by Ulfalussy, et al on the use of intramuscular (im) gold, methotrexate (MTX), and sulfasalazine (SSZ) in psoriatic arthritis (PsA) is very interesting. The lack of difference between time on treatment, calculated by survival analysis, with im gold and MTX observed in this study, contrasts with the results obtained in our study and with other reports.

It is always difficult to explain differences across studies, even more so when treatment is not randomized and the outcome, treatment discontinuation, could be influenced by practice patterns differing across countries. Also, more information about the clinical characteristics of both treatment groups at baseline, about the treatment doses received, and about the results is needed to explore potential reasons for the differences.

I agree with the authors of the letter that non-random allocation of treatment and the fact that some patients having received MTX had failed either im gold or SSZ, are potential explanations for the difference in results observed. If the practice pattern during the study was to reserve MTX for more severe cases or cases refractory to other treatments, this could explain why their results with MTX were less favorable than ours. The authors present information at baseline on age, sex, and disease duration, showing a longer disease duration in the MTX group, but no information regarding disease activity or disease severity. If differences exist at baseline, it would be important to control for them in a multivariate regression analysis, such as a Cox regression analysis, to prevent a confounding effect. To assess whether having used MTX after failure with im gold or SSZ in some of the patients may explain a poorer performance with MTX treatment, one could include order of therapy as a covariate in the Cox regression analysis. Both these analyses were performed in our study and showed that baseline characteristics, other than previous DMARD use, and order of therapy were not significant in our sample. Also, not controlling for repeat observations within patients potentially could dampen a true treatment difference, as patients refractory to all treatments provide multiple observations. The Cox regression method we used allowed the data to be stratified according to first or second treatment course.

It appears that the main difference in the survival results between the 2 studies stems from a shorter survival observed by Ulfalussy, et al for the group receiving MTX [median survival with MTX was 12 months vs more than 5 years in our study (median survival cannot be calculated in our study since less than 50% discontinued treatment, but at 5 years, 54% remained on treatment); whereas median survival with gold was 12 and 14 months, respectively]. Information on the reason for discontinuation may help understand why this difference was observed. Were there more discontinuations for side-effects? If so, it would be interesting to look for differences in practice patterns when dealing with side effects. Or were there more discontinuations for lack of effect? In which case the doses of MTX used in both studies need to be compared. It has been our clinical impression that patients with PsA tend to require higher doses than patients with rheumatoid arthritis.

Finally, the last question to be raised is whether there was a sufficient number of patients taking MTX followed for 2 or more years to have the necessary power to show a difference between the 2 survival curves. Without confidence intervals or number of subjects at risk at different times, it is difficult to assess the certainty of the estimates of survival at 2 years and beyond. The only indication provided is the size of the downward steps on the survival curve, which suggest that the estimates from 2 years onwards are based on relatively small numbers. In our study, although the survival curves appeared different even within the first year, the 95% confidence interval overlapped. The difference between the 2 survival curves became statistically significant only after 1.5 years.

We agree with the conclusion of the authors, that both MTX and im gold are effective treatments, that gold is a good alternative where MTX fails or is contraindicated, and that SSZ, which was not assessed in our study, is another effective treatment, as shown in other controlled studies.

DIANE LACAILLE, MD, MBBS, FRCP; HOWARD B. STEIN, MD, FRCP; JANET RABOUD, MD; ALICE V. KLINKHOF, MD, FRCP; Arthritis Research Centre of Canada; University of British Columbia, Vancouver, Canada.

REFERENCES

Myocarditis Associated with Polymyositis Diagnosed by Gadolinium-DTPA Enhanced Magnetic Resonance Imaging

To the Editor:

Cardiac manifestations of polymyositis include congestive heart failure, pericarditis, pulmonary hypertension, mitral valve prolapse, and dissecting aneurysm, and a variety of arrhythmias have been reported. We describe a case of polymyositis manifesting myocardial insult due to myocarditis, suggested by gadolinium diethylene-triamine-pentaacetic acid enhanced magnetic resonance imaging (Gd-DTPA MRI) and histologically diagnosed by endomyocardial biopsy.

In November 1998, a 58-year-old man was admitted to hospital due to worsening dyspnea because of congestive heart failure. Symmetric proximal muscle wasting and weakness were found in both upper and lower limbs. Right cardiac catheterization showed moderate pulmonary hypertension. Laboratory examination showed a marked elevation of serum muscle enzymes: 1000–1200 IU/l creatine phosphokinase (CPK) (normal < 150 IU/l), 12.3 IU/l aldolase (normal 1.7–5.7 IU/l), and 770 ng/ml myoglobin (normal < 60 ng/ml). His condition improved almost one week after drug treatment, and he was discharged.

In January 1999, he was referred to our university hospital for further examination and treatment. On admission, blood pressure was 132/70 mmHg and his body temperature was 36.8°C. A chest radiograph showed mild cardiomegaly (cardiothoracic ratio 51.9%). The electrocardiogram showed sinus rhythm (heart rate 77 beats/min), negative T waves in leads I, aVL and V4 through V6, and ST depression in leads V4 through V6. Laboratory studies showed 1827 IU/l CPK (muscle origin, MM band, normal 36–216 IU/l), 5.0 IU/l aldolase (normal 0.5–3.1), 988 ng/ml myoglobin (normal < 73 ng/ml), 0.18 ng/ml troponin T (normal < 0.25 ng/ml), and 14 ng/ml myosin light chain (normal < 2.5 ng/ml). He was in NYHA class II. Gd-DTPA MRI performed 4 days after admission revealed transmural contrast enhancement in the anterior, lateral, and posterior wall in the left ventricle (Figure 1A, 1B).

Electromyography revealed a characteristic myopathic pattern. Left deltoid muscle biopsy specimens showed hyaline degeneration, or severely degenerated single muscle fibers mixed with normal muscle fibers (Figure 1C). An echocardiogram showed left ventricular dilatation and diffuse hypokinetic wall motion of the left ventricle. There was no valvular disease. Cardiac catheterization was hemodynamically normal. Biplane left ventriculograms revealed generalized hypokinesis in the wall motion. The ejection fraction was 34%. Selective coronary angiograms showed normal

![Figure 1](https://example.com/figure1.png)

Figure 1. A, B: MRI reveal transmural contrast enhancement in the anterior, lateral, and posterior wall in the left ventricle. C. Left deltoid muscle specimen shows hyaline degeneration or severely degenerated single muscle fibers mixed with normal muscle fibers. D. Left ventricular endomyocardial biopsy specimen shows interstitial fibrosis, edema, cellular cluster, and hypertrophy.
epicardial coronary vasospasm. The left ventricular endomyocardial biopsy specimens showed interstitial fibrosis, edema, cellular cluster, and hypertrophy (Figure 1D).

According to the criteria of Bohn and Peter, the diagnosis was “probable polymyositis” and the case was diagnosed positive based on the criteria of the Japanese Ministry of Health and Welfare.

We diagnosed this patient had cardiac involvement due to polymyositis. Prednisone 60 mg/day was started. On February 15, 1999, because plasma CPK level was still high (688 IU/l), methotrexate 5 mg/week started from the next day. On February 20, 1999, he committed suicide.

Cardiac involvement is one of the most significant clinical factors associated with a poor prognosis for polymyositis. The incidence of cardiac disease in polymyositis was formerly thought to be low, but careful cardiac evaluation has shown it to be much higher. The incidence has been reported as from 37% to 49% in large series.

Haupt, et al reported that pathological evidence of cardiac involvement in patients with polymyositis included active myocarditis, focal fibrosis, vasculitis, intimal proliferation, and medial sclerosis of vessels. On the other hand, Denbow, et al demonstrated that some patients have histological findings of active myocarditis and others show replacement fibrosis and small vessel disease in the myocardium. In the present case, the pathological findings included interstitial fibrosis, edema, and degeneration of the contractile band. These findings suggested the presence of myocardial inflammatory damage.

Gd-DTPA MRI has been used to detect myocardial damage from active myocardial inflammation. A study using a rodent myocarditis model has shown that accumulation of Gd-DTPA is observable in myocarditis with ongoing replacement fibrosis, in both the active inflammation and the healing stage, but not in scar tissue. We have reported that Gd-DTPA is a helpful tool to detect sarcoid heart, eosinophilic myocarditis, ischemic myocardial injury, and subendocardial damage due to aortic valve stenosis.

Gd-DTPA MRI shows the extent and location of inflammation and fibrosis of the myocardium more clearly than myocardium more clearly than myocardial scintigraphy and echocardiography. We should therefore take the possibility of cardiac involvement into consideration when treating patients with polymyositis. Our case demonstrates that Gd-DTPA MRI may be a helpful and safe tool and is more specific for the evaluation of myocardial damage than conventional intravenous techniques.

Gd-DTPA MRI may be a useful screening tool for the diagnosis of myocarditis associated with polymyositis, and can be helpful in providing an appropriate treatment.

SHUZO OHATA, MD; TOSHIKO SHIMADA, MD; HIROMI SHIMIZU, MD; YO MURAKAMI, MD; Cardiovascular Division, Fourth Department of Internal Medicine, Shimane Medical University, 89-1, Enya-cho, Izumo, Shimane 693-8501; YOSHI MATSUO, Division of Cardiology, Matsue City Hospital, 101 Nada-machi, Matsue, Shimane 690-8509, Japan

REFERENCES


Ultrasound Imaging — a Requirement for Rheumatologists

To the Editor:

In an editorial entitled “Ultrasound imaging: A rheumatologist’s dream” I speculated on the impact ultrasonography could have in rheumatologic training. While on the one hand my dream has recently come true, I have also learned that it was no dream at all but ignorance of what is going on in European rheumatology.

My dream was realized when I attended a workshop organized by Dr. Antonio Regnato from The Cooper Health System and the Division of Rheumatology, UMDNJ/Robert Wood Johnson Medical School at Camden, New Jersey, to honor the late Dr. Joseph L. Hollander. The workshop, “Cutting Edge Diagnostic Techniques and Invasive Rheumatology for the Millennium,” took place just before the 2000 American College of Rheumatology Meeting in October in Philadelphia. There were 2 eight-hour sessions devoted to arthroscopy, 2 eight-hour sessions on musculoskeletal ultrasound, plus an eight-hour session on synovial inflations, subcutaneous fat aspiration, skin biopsy, salivary gland biopsy, needle muscle biopsy, anterior iliac crest biopsy, and capillaroscopy. Although I did not attend the arthroscopy sessions those who did were delighted with the hands-on approach in realistic plastic models under the authoritative guidance of Drs. Gil A. Reyes and Angel Checa from Havana, Cuba, and Robert W. Ike from Ann Arbor, Michigan. The ultrasound sessions, which I attended, allowed participants to perform a full upper and lower extremity joint ultrasound in healthy persons plus selected joints in patients with inflammatory joint disease. The superb instructors included Drs. Esperanza Naredo and Jacqueline Uson from Madrid, Spain, Antonio Boffard from Detroit, Michigan, and Walter Grussi from Ancona, Italy. Please note that of the 4 ultrasound instructors one was an American radiologist while the 3 European instructors were rheumatologists with ample experience in musculoskeletal ultrasonography. This session obviously did not make us ultrasonographers, but was enticing enough to send us back trying to figure how to get hold of an ultrasound machine and start exploring the soft tissues. Lecturers in the third session included Drs. Warren R. Heymann, Joseph V.
Campelone, Gerald Falasca, and Antonio J. Reginato from Camden, New Jersey, and Drs. Mary-Carmen Amigo and myself from México City, México. Thanks to Dr. Reginato’s enterprise this session allowed attendants to practice synovial needle placement using realistic plastic models with an internal sensor that indicated accurate placement, and a hands-on true-cut muscle biopsy session in which attendants tried their hand on a Purdue turkey. Truly, I have never seen a workshop like this, in which the fuzzy fringes of our specialty were probed with vigor and knowhow.

That my ultrasonography dream was only ignorance I learned from our European instructors. At present, to qualify as a rheumatologist in Italy one has to provide evidence of having performed 200 ultrasonic examinations plus 200 arthroscopic examinations. Ultrasound proficiency is also required in Austria, Germany, and Switzerland. Work is in progress to require ultrasonography proficiency in other European countries.

There is no question that emphasis on biology and experimental medicine, and more recently clinical epidemiology, has built the greatness of rheumatology in the New World. However, to fulfill our duty as specialists in diseases of the musculoskeletal system (which comprise about 30% of our day to day practice) we must become proficient in musculoskeletal medicine. To this end, musculoskeletal ultrasonography provides an unmatched medium. Dr. Reginato’s far-seeing, successful workshop should be replicated and expanded by American (in the broad sense) academic rheumatology. The 3 workshop sessions on ultrasonography featured at the San Francisco ACR meeting with a German instructor, Prof. Wolfgang Schmidt, and the musculoskeletal ultrasound study group, represent steps in the right direction.

JUAN J. CANOSO, MD, ABC Hospital, México City, México. E-mail: juan123canoso@prodigy.net.mx

REFERENCE

Canadian Consensus Conference on Hydroxychloroquine

To the Editor:
In the December 2000 issue the report of the Canadian Consensus Conference on hydroxychloroquine, chaired by Dr. John Esdaile, was published. One of the key recommendations was the need to develop up-to-date “patient friendly” information to meet the needs of consumers. In followup to this recommendation, a consumer led workshop was held recently that included representatives of the Canadian Rheumatology Association, Canadian Pharmacists Association, Canadian Ophthalmology Society, Canadian Paediatric Rheumatology Association, Motherisk Canada, Lupus Canada, Canadian Arthritis Patient Alliance, The Arthritis Society, and Health Canada.

In keeping with emerging Therapeutic Products Directorate guidelines, the patient information drafted by this group will be submitted to Health Canada for inclusion in the hydroxychloroquine product monograph that is currently being developed between Health Canada and the manufacturer.

This group process represented an effective prototype for the development of information that will meet the needs of patients and consumers.

CHERYL L. KOEHN, Chair, Workshop Group, Information to the Patient and Physician on Hydroxychloroquine, ACE Planning & Consulting Inc., 4038 West 38th Avenue, Vancouver, BC V6N 2Y9, Canada.
E-mail: cherylkoehn@telus.net
Corrections

Patberg WR, Rasker JJ. Beneficial effect of being outdoors in rheumatoid arthritis [letter]. J Rheumatol 2002;29:202-4. Labels identifying time periods were omitted from Figure 1, and are printed correctly here. We regret the error.

Lee YH, Kim YR, Ji JD, Sohn J, Song GG. p53 codon 72 polymorphism and rheumatoid arthritis. J Rheumatol 2001;28:2392-4. Acknowledgment of support for this article by a grant from the Korea Ministry of Health and Welfare was omitted. We regret the error.

Figure 1. Plot of 24 hour mean outdoor temperature, time outdoors per 24 hours, daily joint pain score, and ESR. Periods during which the daily time outdoors was about 3 hours are shaded. Broken lines (JS) indicate days on which joint surgery was carried out.